This program focuses on frontline therapies for patients with metastatic melanoma. It discusses strategies for sequencing immune checkpoint inhibitors (ICIs) and patient characteristics that guide choice of treatment. The program includes topics such as the scientific rationale driving research, efficacy and safety data from recent pivotal clinical trials, and clinical management dilemmas. This program provides busy clinicians with an opportunity to listen to experts discuss critical takeaways from research studies and implications for current practice, such as treatment selection and effective management of treatment-related adverse events (AEs). Learners will be able to better understand optimal treatment sequencing while becoming more aware of clinical challenges associated with immunotherapy, such as toxicity management as well as difficult patient scenarios.
Facebook Comments